Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03150602
Other study ID # FOT14-TW-401
Secondary ID
Status Recruiting
Phase Phase 4
First received May 5, 2017
Last updated May 10, 2017
Start date August 30, 2016
Est. completion date December 31, 2020

Study information

Verified date May 2017
Source Taiwan Mundipharma Pharmaceuticals Ltd.
Contact Bor-Sheng Ko, PhD
Phone 886-23123456
Email kevinkomd@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is to evaluate the objective response rate to pralatrexate in Asian PTCL patients after prior treatment failure, as determined by independent imaging reviewer(s) using international workshop lymphoma response criteria (IWC)


Description:

Peripheral T-cell lymphomas (PTCL) are a group of aggressive and diverse lymphoproliferative disorders. It is characterized by the presence of malignant mature T-cells or NK cells. There is as yet no consensus regarding standard frontline or relapsed/refractory therapy for PTCL.

A previous phase II study conducted in US showed durable responses of pralatrexate treatment in relapsed or refractory PTCL, irrespective of age, histological subtypes, amount of prior therapy, prior methotrexate, and prior autologous stem-cell transplant. This single-arm, multi-center study aims to evaluate the efficacy and safety of pralatrexate monotherapy in prior treatment failure PTCL patients who may undergo HSCT in case of CR or PR, or continue pralatrexate in case of CR, PR or SD.

Primary objective:

- To evaluate the objective response rate to pralatrexate in Asian PTCL patients after prior treatment failure, as determined by independent imaging reviewer(s) using international workshop lymphoma response criteria (IWC)

Secondary objectives:

- To determine the safety of pralatrexate in Asian PTCL patients by,

- Incidence of adverse events (AEs) and serious adverse events (SAEs) emergent from the treatment

- To evaluate the efficacy of pralatrexate in Asian PTCL patients after prior treatment failure by,

- Overall survival (OS), progression-free-survival (PFS), complete response (CR) and partial response (PR) rate, and duration of CR and PR

- Treatment duration with pralatrexate in the patients without hematopoietic stem cell transplant (HSCT) who achieve CR or PR

- Percentage of patients who undergo HSCT

- 1-year OS, 1-year PFS, and 1-year relapse rate after HSCT

- 2-year OS, 2-year PFS, and 2-year relapse rate after HSCT


Recruitment information / eligibility

Status Recruiting
Enrollment 22
Est. completion date December 31, 2020
Est. primary completion date December 31, 2020
Accepts healthy volunteers No
Gender All
Age group 20 Years and older
Eligibility Inclusion Criteria:

1. At least 20 years of age, inclusive

2. Patients with histologically/cytologically confirmed PTCL using either: NCCN diagnosis criteria, the Revised European American Lymphoma (REAL), and World Health Organization (WHO) disease classification (PTCL histology/cytology subtypes diagnosed by site investigators, PTCL histology/cytology subtypes rechecked by study central pathology lab):

1. At least 5 patients with Peripheral T-cell lymphoma, NOS

2. At least 5 patients with Angioimmunoblastic T-cell lymphoma

3. At least 5 patients with Extranodal NK/T-cell lymphoma, nasal type

4. Enteropathy-type T-cell lymphoma

5. Hepatosplenic T-cell lymphoma

6. Subcutaneous panniculitis-like T-cell lymphoma

7. Adult T-cell lymphoma/leukemia (human T-cell leukemia virus [HTLV] 1+)

3. Patients with documented progressive disease (PD) failed after prior treatment

1. Patients may not have received an experimental drug as their only prior therapy

2. Patient has had at least 1 biopsy from initial diagnosis of PTCL or in the relapsed setting to confirm PTCL subtypes

3. Patient has recovered from the toxic effects of prior therapy

4. Eastern Cooperative Oncology Group (ECOG) Performance Status = 2.

5. Adequate hematological, hepatic, and renal function as defined by: absolute neutrophil count (ANC) = 1000/µL, platelet count = 100,000/µL (and = 50,000/µL for any following dose), total bilirubin = 1.5 mg/dL, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) = 2.5 X upper limit of normal (ULN) (AST/ALT < 5 X ULN if documented hepatic involvement with lymphoma), creatinine = 1.5 mg/dL or a calculated creatinine clearance = 50 mL/min.

6. Women of childbearing potential must agree to practice medically acceptable contraceptive regimen from 30 days prior to study treatment initiation until at least 30 days after the last administration of pralatrexate and must have had a negative serum pregnancy test within 14 days prior to the first day of study treatment. Patients who are postmenopausal for at least 1 year (> 12 months since last menses) or were surgically sterilized do not require this test.

7. Men who are not surgically sterile must agree to practice a medically acceptable contraceptive regimen from study treatment initiation until at least 90 days after the last administration of pralatrexate.

8. Patient has provided written informed consent (IC)

Exclusion Criteria:

1. Patient has following subtypes (histologically/cytologically confirmed) of PTCL

1. Anaplastic large cell lymphoma, ALK +/-

2. Patient has: Precursor T/NK neoplasms, with the exception of blastic NK lymphoma

3. T-cell prolymphocytic leukemia (T-PLL)

4. T-cell large granular lymphocytic leukemia

5. Mycosis fungoides and transformed mycosis fungoides

6. Sézary syndrome

7. Primary cutaneous CD30+ disorders: Anaplastic large cell lymphoma and lymphomatoid papulosis

8. Patient has: Extranodal NK/T-cell lymphoma, nasal type with local recurrence

2. Active concurrent malignancy (except for non-melanoma skin cancer or carcinoma in situ of the cervix). If there is a history of prior malignancy, the patient must be disease-free for = 5 years.

3. Congestive heart failure Class III/IV according to the New York Heart Association's Heart Failure guidelines.

4. Patients with human immunodeficiency virus (HIV)-positive diagnosis and are receiving combination anti-retroviral therapy.

5. Current or the history of brain metastases or central nervous system (CNS) diseases

6. Have undergone allogeneic stem cell transplant

7. Relapsed less than 75 days from time of autologous stem cell transplant

8. Patients with uncontrolled hypertension, active uncontrolled infection, underlying medical condition including unstable cardiac disease, or other serious illness that would impair the ability of the patient to receive protocol treatment

9. Had major surgery within 2 weeks of study entry

10. Receipt of any conventional chemotherapy or radiation therapy (RT) within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to study treatment or planned use during the course of the study

11. Receipt of corticosteroids within 7 days of study treatment, unless patient has been taking a stable dose of no more than 10 mg/day of prednisone for at least 1 month

12. Use of any investigational drug, biologic modifier, or device within 4 weeks prior to study treatment or planned use during the course of the study

13. Previous exposure to pralatrexate

14. Other conditions that investigators consider not suitable for study enrollment

Study Design


Intervention

Drug:
Pralatrexate
This is a single arm study. Pralatrexate will be administered via IV over 3-5 minutes into a IV line containing normal saline (0.9% sodium chloride, NaCl) with the initial dose of 30 mg/m2/week on days 1, 8, 15, 22, 29, and 36 for 6 weeks in a 7-week cycle. The scheduled date can be done within a window time of plus or minus 1 day. The pralatrexate dose may be reduced to 20 mg/m2/week or omit if a patient experiences adverse events. Pralatrexate administration can be up to 5 cycles or until subject meets withdrawal criteria.

Locations

Country Name City State
Taiwan Ntional Taiwan University Hospital Taipei

Sponsors (1)

Lead Sponsor Collaborator
Taiwan Mundipharma Pharmaceuticals Ltd.

Country where clinical trial is conducted

Taiwan, 

References & Publications (7)

Krug LM, Ng KK, Kris MG, Miller VA, Tong W, Heelan RT, Leon L, Leung D, Kelly J, Grant SC, Sirotnak FM. Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate. Clin Cancer Res. 2000 Sep;6(9):3493-8. Erratum in: Clin Cancer Res 2001 Apr;7(4):1102. — View Citation

O'Connor OA, Pro B, Pinter-Brown L, Bartlett N, Popplewell L, Coiffier B, Lechowicz MJ, Savage KJ, Shustov AR, Gisselbrecht C, Jacobsen E, Zinzani PL, Furman R, Goy A, Haioun C, Crump M, Zain JM, Hsi E, Boyd A, Horwitz S. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol. 2011 Mar 20;29(9):1182-9. doi: 10.1200/JCO.2010.29.9024. Epub 2011 Jan 18. — View Citation

Savage KJ, Harris NL, Vose JM, Ullrich F, Jaffe ES, Connors JM, Rimsza L, Pileri SA, Chhanabhai M, Gascoyne RD, Armitage JO, Weisenburger DD; International Peripheral T-Cell Lymphoma Project.. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood. 2008 Jun 15;111(12):5496-504. doi: 10.1182/blood-2008-01-134270. Epub 2008 Apr 2. — View Citation

Savage KJ. Peripheral T-cell lymphomas. Blood Rev. 2007 Jul;21(4):201-16. Epub 2007 May 18. Review. — View Citation

Shustov A. Novel therapies for peripheral T-cell lymphomas. Ther Adv Hematol. 2013 Jun;4(3):173-87. doi: 10.1177/2040620713481980. — View Citation

Society TLL, Peripheral T-Cell Lymphoma Facts, 2014.

Wang ES, O'Connor O, She Y, Zelenetz AD, Sirotnak FM, Moore MA. Activity of a novel anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression. Leuk Lymphoma. 2003 Jun;44(6):1027-35. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Objective Response Rate Objective response rate (ORR) to pralatrexate treatment in Asian PTCL patients after prior treatment failure, as determined by independent imaging reviewer(s) using international workshop lymphoma response criteria (IWC) Up to 35 weeks
Secondary Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] Incidence of adverse events (AE) and serious adverse events (SAE) emergent from the treatment Up to 40 weeks
Secondary Overall survival Duration of overall survival (months) Up to 5 years
Secondary Progression-free survival Duration of PFS (months) Up to 5 years
Secondary Completion response rate The percentage of CR Up to 5 years
Secondary Partial response rate The percentage of PR Up to 5 years
Secondary Duration of CR and PR Duration of completion response and partial response (days) Up to 5 years
Secondary Treatment duration Treatment duration with pralatrexate in the patients without HSCT who achieve CR or PR Up to 35 weeks
Secondary Hematopoietic stem cell transplant (HSCT) Percentage of patients who undergo HSCT Up to 5 years
Secondary 1-year OS rate after HSCT 1-year overall survival rate after conducting HSCT Up to 1 year
Secondary 1-year PFS rate after HSCT 1-year progression-free survival rate after conducting HSCT Up to 1 year
Secondary 1-year relapse rate after HSCT 1-year relapse rate after conducting HSCT Up to 1 year
Secondary 2-year OS rate after HSCT 2-year overall survival rate after conducting HSCT Up to 2 years
Secondary 2-year PFS rate after HSCT 2-year progression-free survival rate after conducting HSCT Up to 2 years
Secondary 2-year relapse rate after HSCT 2-year relapse rate after conducting HSCT Up to 2 years
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04526834 - Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma Phase 1
Recruiting NCT04390737 - Evaluate the Safety and Clinical Activity of HH2853 Phase 1/Phase 2
Recruiting NCT05559008 - A Umbrella Study in R/R PTCL Guided by Molecular Subtypes Phase 1/Phase 2
Recruiting NCT06083701 - Phase I/II Study of Linperlisib Plus Chidamide for R/R Peripheral T-cell Lymphoma: a Prospective, Multi-center Study Phase 1/Phase 2
Not yet recruiting NCT02856997 - Chidamide With ICE Regimen for Relapsed/Refractory Peripheral T Cell Lymphoma Phase 2
Recruiting NCT04083495 - CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma Phase 2
Not yet recruiting NCT05979792 - Clinical Study of CD7 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory CD7-positive Peripheral T Cell Lymphoma Early Phase 1
Recruiting NCT04984837 - Study of Lacutamab in Peripheral T-cell Lymphoma Phase 2
Recruiting NCT06072131 - To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL Phase 3
Completed NCT01716806 - A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL) Phase 2
Terminated NCT03947255 - A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma Phase 2
Recruiting NCT04028440 - γδT Cells Immunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL) Early Phase 1
Not yet recruiting NCT05923502 - (CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL)
Recruiting NCT05377827 - Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies Phase 1
Recruiting NCT05883449 - Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL Phase 2
Active, not recruiting NCT03586999 - Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas Phase 1/Phase 2
Recruiting NCT04489264 - The Role of Consolidative Autologous Stem Cell Transplantation After First-line Therapy in Peripheral T Cell Lymphoma
Recruiting NCT06151106 - Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma Phase 2
Recruiting NCT02753543 - Chidamide Plus Chemotherapy in the Treatment of Peripheral T-cell Lymphoma Phase 2
Not yet recruiting NCT06089941 - Circulating Tumor DNA Sequencing in Patients With Peripheral T-cell Lymphomas